Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-center, open-labelled randomized controlled trial, to study the effect of aspirin plus cilostazol and aspirin alone on the progression of intracranial arterial stenosis, in 200 chronic stroke patients with 50-99% stenosis, to be followed up for 2 years

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intracraial arterial stenosis (IAS) is more common in Asia, including Japanese, than in Cocasian. Also, stroke recurrence rate is high in patients with such lesions, despite medical treatment. Accoding to the result of WASID (N Engl J Med 2005;352:1305-16), warfarin is not recommended because of the concern of safety (higher risk of intracranial hemorrhage and death when compared with aspirin), wheras the efficacy of aspirin is not enough in symptomatic IAS patients. Under these conditions, we planned to conduct a nationwide multi-center, open labelled, randomized controlled trial to compare the effect of aspirin plus cilostazol (phosphodiestrase type 3 inhibitor) and aspirin alone on the progression of IAS in 200 IAS patients with ischemic stroke after 2 weeks to 6 months of onset. Patients are randomly allocated to either of two groups. Aspirin 100mg/day plus cilostazol 200 mg/day is given to the 100 patients in one group, and aspirin 100 mg/day alone is given to 100 patients in another group.

Follow-up period is at least two years. The primary endpoint is progression of IAS on MRA at two years after randomization. The secondary endpoints are cardiovascular events (ischemic stroke, myocardial infarct, and other vascular events), death, serious adverse events, new silent brain infarcts, and activity of daily life. The purpose of this study is to establish the best medical treatment in symptomatic IAS patients. This study will also provide important information for the future randomized controlled study to compare medical treatment alone and intravascular intervetnion (PTA and/or stenting) in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

intracranial arteriosclerosis cilostazol Platelete aggrigation inhibitors dual antiplatelet therapy Drug therapy, combination Clinical trials

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Asprin, Cilostazol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Ischemic stroke after two weeks to six months from onset,
* (2) Responsible lesion identified on MRI,
* ( 3) Intracranial arterial stenosis \>50% on MRA in the territory of responsible lesion,
* (4) Intracranial arterial stenosis in suproclinoid internal carotid arterry, M1 portion of midlle cerebral artery, or basilar artery,
* (5) Age of 45 to 85 years,
* (6) Able to visit out-patient clinic, and
* (7) Written informed consent obtained from patient or family.

Exclusion Criteria

* (1) Patients with potential cardiac embolic sources,
* (2) Patients receiving cilostazol,
* (3) Patients on warfarin treatment,
* (4) Patients in whom MRI cannot be perfomed,
* (5) Patients in whom PTA or bypass surgery is planned,
* (6) Patients with history of symptomatic intracranial hemorrhage, other hemorrhagic diseases (active peptic ulcer etc.), hemophilia or coagulation abnormalities,
* (7) Patients with hypersensitivity to cilostazol or aspirin,
* (8) Patients with congestive heart failure or uncontrollable angina pectoris,
* (9) Patients with thrombocytopenia (\<100,000/mm3),
* (10) Patients with liver dysfunction (AST or ALT \>100 IU/L),
* (11) Patients with renal dysfunction (Creatinin \>2.0 mg/dl),
* (12) Patients who cannot to be followed up during the study period,
* (13) Patients who are enrolled in other clinical trials, and
* (14) Patients inadequate for this study by other reasons.

Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shinichiro Uchiyama, M.D. PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Neurology, Tokyo Women's Medical University School of Medicine

Nobuyuki Sakai, M.D. PhD

Role: PRINCIPAL_INVESTIGATOR

Kobe City General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tokyo Women's Medical University School of Medicine

Shinjuku-ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UHA STROKE04-01

Identifier Type: -

Identifier Source: org_study_id